PH31631A - Serotonerbic tetrahydropyridoindoles. - Google Patents
Serotonerbic tetrahydropyridoindoles.Info
- Publication number
- PH31631A PH31631A PH51266A PH51266A PH31631A PH 31631 A PH31631 A PH 31631A PH 51266 A PH51266 A PH 51266A PH 51266 A PH51266 A PH 51266A PH 31631 A PH31631 A PH 31631A
- Authority
- PH
- Philippines
- Prior art keywords
- optionally substituted
- alkyl
- hydrogen
- substituted phenyl
- trifluoromethyl
- Prior art date
Links
- UFXNNGDEYWTROW-UHFFFAOYSA-N 2,3,3a,4-tetrahydro-1h-pyrrolo[2,3-f]quinoline Chemical class C1C=C2N=CC=CC2=C2C1CCN2 UFXNNGDEYWTROW-UHFFFAOYSA-N 0.000 title 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 8
- 239000001257 hydrogen Substances 0.000 abstract 5
- 229910052739 hydrogen Inorganic materials 0.000 abstract 5
- 125000001072 heteroaryl group Chemical group 0.000 abstract 4
- 150000002431 hydrogen Chemical class 0.000 abstract 4
- 125000001624 naphthyl group Chemical group 0.000 abstract 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 4
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 3
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 125000001475 halogen functional group Chemical group 0.000 abstract 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 abstract 1
- 239000005864 Sulphur Chemical group 0.000 abstract 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract 1
- 210000003169 central nervous system Anatomy 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 125000004185 ester group Chemical group 0.000 abstract 1
- 239000001301 oxygen Substances 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 230000000862 serotonergic effect Effects 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Cardiology (AREA)
- Obesity (AREA)
- Otolaryngology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Child & Adolescent Psychology (AREA)
- Anesthesiology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Urology & Nephrology (AREA)
- Addiction (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Steroid Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Plural Heterocyclic Compounds (AREA)
- Holo Graphy (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB9418326A GB9418326D0 (en) | 1994-09-12 | 1994-09-12 | Pharmaceutical compounds |
| GBGB9511166.2A GB9511166D0 (en) | 1995-06-02 | 1995-06-02 | Pharmaceutical compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PH31631A true PH31631A (en) | 1999-01-12 |
Family
ID=26305611
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PH51266A PH31631A (en) | 1994-09-12 | 1995-09-08 | Serotonerbic tetrahydropyridoindoles. |
Country Status (22)
| Country | Link |
|---|---|
| EP (1) | EP0705832B1 (no) |
| JP (1) | JPH0881464A (no) |
| KR (1) | KR960010635A (no) |
| CN (1) | CN1045602C (no) |
| AT (1) | ATE247114T1 (no) |
| AU (1) | AU698580B2 (no) |
| CA (1) | CA2157998A1 (no) |
| CZ (1) | CZ286565B6 (no) |
| DE (1) | DE69531476T2 (no) |
| ES (1) | ES2204932T3 (no) |
| FI (1) | FI954243A7 (no) |
| HU (1) | HU219491B (no) |
| IL (1) | IL115236A (no) |
| IN (1) | IN179550B (no) |
| MY (1) | MY132009A (no) |
| NO (1) | NO305174B1 (no) |
| NZ (1) | NZ272961A (no) |
| PE (1) | PE41796A1 (no) |
| PH (1) | PH31631A (no) |
| PL (1) | PL310373A1 (no) |
| RU (1) | RU2146256C1 (no) |
| TR (1) | TR199501114A2 (no) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2308362A (en) * | 1995-12-19 | 1997-06-25 | Lilly Industries Ltd | Pharmaceutical indole derivatives |
| EP0905136A1 (en) * | 1997-09-08 | 1999-03-31 | Janssen Pharmaceutica N.V. | Tetrahydro gamma-carbolines |
| UA70334C2 (en) * | 1998-10-06 | 2004-10-15 | Janssen Pharmaceutica N V Jans | BENZOTHIENO[3,2-c]PYRIDINES AS a2 ANTAGONISTS BENZOTHIENO[3,2-c]PYRIDINES AS a2 ANTAGONISTS |
| UA74826C2 (en) * | 2000-05-17 | 2006-02-15 | Ortho Mcneil Pharm Inc | ?-carboline derivatives as phosphodiesterase inhibitors |
| AU7887501A (en) * | 2000-07-06 | 2002-01-21 | Us Gov Health & Human Serv | Tetrahydrobenzothiazole analogues as neuroprotective agents |
| DE10040016A1 (de) * | 2000-08-16 | 2002-02-28 | Boehringer Ingelheim Pharma | Neue beta-Amyloid Inhibitoren, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel |
| JP5062939B2 (ja) * | 2000-09-19 | 2012-10-31 | ベーリンガー インゲルハイム ファルマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト | セロトニン受容体及びドーパミン受容体にアフィニティーを示す新規ｎ，ｎ’−二置換ベンゾイミダゾロン誘導体 |
| AU2002223528A1 (en) * | 2000-09-19 | 2002-04-02 | Boeringer Ingelheim Pharma Gmbh & Co. Kg | New n, n'-disubstituted benzimidazolone derivatives with affinity at the serotonin and dopamine receptors |
| US6586435B2 (en) | 2000-09-19 | 2003-07-01 | Boehringer Ingelheim Pharma Kg | Benzimidazolone derivatives displaying affinity at the serotonin and dopamine receptors |
| US7183410B2 (en) | 2001-08-02 | 2007-02-27 | Bidachem S.P.A. | Stable polymorph of flibanserin |
| CA2453537A1 (en) | 2001-08-08 | 2003-02-20 | Pharmacia & Upjohn Company | Therapeutic 1h-pyrido¬4,3-b|indoles |
| US10675280B2 (en) | 2001-10-20 | 2020-06-09 | Sprout Pharmaceuticals, Inc. | Treating sexual desire disorders with flibanserin |
| UA78974C2 (en) | 2001-10-20 | 2007-05-10 | Boehringer Ingelheim Pharma | Use of flibanserin for treating disorders of sexual desire |
| RU2232578C1 (ru) * | 2003-04-10 | 2004-07-20 | Ахапкина Валентина Ивановна | Вещество, обладающее антидепрессивной активностью |
| JP2009503020A (ja) | 2005-08-03 | 2009-01-29 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 肥満症の治療におけるフリバンセリンの使用 |
| CA2626134C (en) | 2005-10-29 | 2013-12-24 | Boehringer Ingelheim International Gmbh | Benzimidazolone derivatives for the treatment of premenstrual and other female sexual disorders |
| EP2037927B1 (en) | 2006-06-30 | 2010-01-27 | Boehringer Ingelheim International GmbH | Flibanserin for the treatment of urinary incontinence and related diseases |
| CL2007002214A1 (es) | 2006-08-14 | 2008-03-07 | Boehringer Ingelheim Int | Composicion farmaceutica en la forma de comprimido, donde al menos la longitud del comprimido en el estado anterior de la aplicacion es al menos 7/12 del diametro pilorico del paciente y despues de ingerirlo en estado alimentado, la longitud del comp |
| JP5793828B2 (ja) | 2006-08-14 | 2015-10-14 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | フリバンセリンの製剤及びその製造方法 |
| KR20090045945A (ko) | 2006-08-25 | 2009-05-08 | 베링거 인겔하임 인터내셔날 게엠베하 | 제어 방출 시스템 및 이의 제조방법 |
| CL2008002693A1 (es) | 2007-09-12 | 2009-10-16 | Boehringer Ingelheim Int | Uso de flibanserina para el tratamiento de sintomas vasomotores seleccionados de sofocos, sudores nocturnos, cambios de estado de animo e irritabilidad |
| MX2011012537A (es) | 2009-05-29 | 2011-12-14 | Sumitomo Chemical Co | Agente para el tratamiento o prevencion de enfermedades asociadas con actividad de factores neurotroficos. |
| KR20240142622A (ko) * | 2015-10-01 | 2024-09-30 | 올레마 파마슈티컬스 인코포레이티드 | 테트라히드로-1H-피리도[3,4-b]인돌 항에스트로겐 약물 |
| KR20220034129A (ko) | 2019-07-07 | 2022-03-17 | 올레마 파마슈티컬스 인코포레이티드 | 에스트로겐 수용체 길항제 요법 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4035369A (en) | 1975-10-08 | 1977-07-12 | Janssen Pharmaceutica N.V. | 1-Benzazolylalkyl-4-substituted-piperidines |
| IL69132A (en) * | 1982-07-14 | 1986-02-28 | Roussel Uclaf | Benzo-and naphtho-thiopyranopyrimidinones,their preparation and pharmaceutical compositions containing them |
| US4636563A (en) * | 1985-09-16 | 1987-01-13 | American Home Products Corporation | Antipsychotic γ-carbolines |
| FR2661177A1 (fr) * | 1990-04-23 | 1991-10-25 | Rhone Poulenc Sante | Derives du naphtosultame antagonistes de la serotonine, leur preparation et les medicaments les contenant. |
-
1995
- 1995-09-07 DE DE69531476T patent/DE69531476T2/de not_active Expired - Fee Related
- 1995-09-07 ES ES95306253T patent/ES2204932T3/es not_active Expired - Lifetime
- 1995-09-07 AT AT95306253T patent/ATE247114T1/de not_active IP Right Cessation
- 1995-09-07 EP EP95306253A patent/EP0705832B1/en not_active Expired - Lifetime
- 1995-09-08 HU HU9502631A patent/HU219491B/hu not_active IP Right Cessation
- 1995-09-08 CZ CZ19952322A patent/CZ286565B6/cs not_active IP Right Cessation
- 1995-09-08 NZ NZ272961A patent/NZ272961A/en unknown
- 1995-09-08 PH PH51266A patent/PH31631A/en unknown
- 1995-09-08 MY MYPI95002675A patent/MY132009A/en unknown
- 1995-09-08 AU AU30497/95A patent/AU698580B2/en not_active Ceased
- 1995-09-11 JP JP7231873A patent/JPH0881464A/ja active Pending
- 1995-09-11 PL PL95310373A patent/PL310373A1/xx unknown
- 1995-09-11 CA CA002157998A patent/CA2157998A1/en not_active Abandoned
- 1995-09-11 IL IL115236A patent/IL115236A/en not_active IP Right Cessation
- 1995-09-11 IN IN1079CA1995 patent/IN179550B/en unknown
- 1995-09-11 NO NO953575A patent/NO305174B1/no not_active IP Right Cessation
- 1995-09-11 RU RU95115522A patent/RU2146256C1/ru active
- 1995-09-11 KR KR1019950029475A patent/KR960010635A/ko not_active Ceased
- 1995-09-11 FI FI954243A patent/FI954243A7/fi unknown
- 1995-09-11 CN CN95117133A patent/CN1045602C/zh not_active Expired - Fee Related
- 1995-09-12 PE PE1995278830A patent/PE41796A1/es not_active Application Discontinuation
- 1995-09-12 TR TR95/01114A patent/TR199501114A2/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN1045602C (zh) | 1999-10-13 |
| NZ272961A (en) | 1998-02-26 |
| PE41796A1 (es) | 1996-10-21 |
| CZ232295A3 (en) | 1996-03-13 |
| RU2146256C1 (ru) | 2000-03-10 |
| DE69531476T2 (de) | 2004-06-09 |
| CA2157998A1 (en) | 1996-03-13 |
| CZ286565B6 (cs) | 2000-05-17 |
| DE69531476D1 (de) | 2003-09-18 |
| HUT72593A (en) | 1996-05-28 |
| FI954243A0 (fi) | 1995-09-11 |
| EP0705832A1 (en) | 1996-04-10 |
| NO305174B1 (no) | 1999-04-12 |
| JPH0881464A (ja) | 1996-03-26 |
| KR960010635A (ko) | 1996-04-20 |
| IL115236A (en) | 1998-06-15 |
| NO953575D0 (no) | 1995-09-11 |
| AU3049795A (en) | 1996-03-28 |
| CN1129219A (zh) | 1996-08-21 |
| NO953575L (no) | 1996-03-13 |
| HU9502631D0 (en) | 1995-11-28 |
| HU219491B (hu) | 2001-04-28 |
| ES2204932T3 (es) | 2004-05-01 |
| FI954243A7 (fi) | 1996-03-13 |
| ATE247114T1 (de) | 2003-08-15 |
| IN179550B (no) | 1997-10-18 |
| IL115236A0 (en) | 1995-12-31 |
| PL310373A1 (en) | 1996-03-18 |
| TR199501114A2 (tr) | 1996-10-21 |
| EP0705832B1 (en) | 2003-08-13 |
| AU698580B2 (en) | 1998-11-05 |
| MY132009A (en) | 2007-09-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH31631A (en) | Serotonerbic tetrahydropyridoindoles. | |
| IL123142A0 (en) | The use of adamantan-derivatives for the treatment of the inner ear | |
| NZ334976A (en) | Benzonaphthyridine derivatives and their use for treating airway disorders and dermatoses | |
| AU5898580A (en) | Pyroglutamic acid derivatives | |
| AU4523797A (en) | Atherosclerosis treatment | |
| AU3113793A (en) | Intermediates for preparing antipicornaviral pyridazinamines | |
| PT918776E (pt) | Sintese total de acilfulvenos antitumorais | |
| AU667593B2 (en) | Inhibitors of HIV protease useful for the treatment of AIDS | |
| DE69707372D1 (de) | Verwendung eines Phosphorsäurediesters zur Herstellung eines Arzneimittels zur Behandlung von Akne | |
| HUP9902992A3 (en) | Alpha-amino acid amides, preparation thereof and pharmaceutical compositions containing them | |
| NO304314B1 (no) | Cykloheksanderivater og anvendelse av forbindelsene for fremstilling av legemidler | |
| GR3000904T3 (en) | Amide derivatives | |
| EP0785193A4 (en) | ARYLTHIADIAZOLE DERIVATIVES AND ANTIVIRAL PRODUCTS CONTAINING THEM | |
| ES8707939A1 (es) | Procedimiento para preparar derivados de n-carboxialquil-2--oxo-3-diaril-5,6-triazinas | |
| TW275629B (no) | ||
| NO972942L (no) | 4-amino-2-ureido-pyrimidin-5-karboksylsyreamider, fremgangsmåter for deres fremstilling, legemidler inneholdende disse forbindelsene og deres anvendelse |